Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

NAD+ Activate Ingredients & Drug Interactions

by DaVinci Laboratories

NAD+ Activate label
See full label image
Capsule Category: Other Combinations
Most serious interaction: Moderate
Clinical methodology reviewed by · Updated Sep 23, 2026 · Label data from the NIH DSLD
What is this page for?

First and foremost: checking NAD+ Activate against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.

Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy

The interaction bottom line Most serious interaction: Moderate

NAD+ Activate is a dietary supplement by DaVinci Laboratories with 4 active ingredients. Its ingredients are commonly taken for high cholesterol, vitamin b3 deficiency (pellagra), heart health support.Based on those ingredients, 801 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Niacin, Vitamin C, Ribose. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

Jump to a section

Check Your Meds Against NAD+ Activate by DaVinci Laboratories

Ask about any prescription or over-the-counter medication and we check it for interactions with NAD+ Activate by DaVinci Laboratories — and tell you which ingredient is responsible.

Pharmacist-reviewed data Checks every ingredient Answer in seconds
Prefer a human? Send your question to our licensed pharmacists — free, answered by email within 24 hours.

HelloPharmacist Scorecard of NAD+ Activate by DaVinci Laboratories

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

Generated from HelloPharmacist’s pharmacist-curated databases and editorial rules · Last generated Jul 11, 2026

What’s inside

Partial disclosure
Ingredient Transparency · database check
Partial

Most active ingredients list an amount, but at least one is hidden in a blend or missing.

Why this rating?
  • The label discloses an exact amount for 2 of its 4 active ingredients.
  • “Bioenergy RiaGev-WS” is listed as a grouped ingredient — the label gives one combined amount (750 mg) without saying how much of each component you get.

NAD+ Activate contains four active ingredients. Niacin (also called vitamin B3) is included for its role in energy metabolism and cellular repair.

Vitamin C is an antioxidant that supports immune function. Ribose is a simple sugar that plays a role in energy production within cells.

The product also contains Nicotinamide Ascorbate — a form of nickel — and a proprietary blend called Bioenergy RiaGev-WS. The remaining ingredients are inactive: hypromellose, microcrystalline cellulose, and leucine are used as capsule material and binders.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: support cellular energy.
  • We looked for evidence on: Athletic performance, Chronic fatigue syndrome (CFS), Exercise-induced muscle damage, Exercise-induced respiratory infections, Fibromyalgia, Heart transplant complications — and 4 related terms.
  • The strongest evidence on file: Niacin is rated "Possibly Effective" for Metabolic syndrome (Natural Medicines).
  • Also on file: Vitamin C is rated "Possibly Effective" for Exercise-induced respiratory infections, Hypercholesterolemia.
  • Also on file: Ribose is rated "Possibly Ineffective" for Athletic performance.

The evidence for this product's ingredients varies. Niacin is likely effective for pellagra (a vitamin B3 deficiency disease) and possibly effective for abnormal cholesterol related to HIV/AIDS and metabolic syndrome.

Vitamin C is effective for vitamin C deficiency and possibly effective for anemia, cataracts, and exercise-related respiratory infections. The data we hold shows that ribose's effectiveness is uncertain — studies rate it as possibly ineffective for athletic performance and muscle soreness, and there isn't enough reliable evidence to rate it for heart failure or restless legs syndrome.

We have no effectiveness data on file for Nicotinamide Ascorbate or Bioenergy RiaGev-WS.

The evidence, ingredient by ingredient Niacin Vitamin C Ribose Nickel

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 4 of the 4 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 4 of 4.
  • General safety write-ups exist for 4 of 4.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Niacin is generally well tolerated at normal dietary amounts, but high-dose supplements can cause flushing (affecting up to 70% of people taking therapeutic doses), stomach problems like nausea and heartburn, and liver damage — especially with time-release forms. Rarely, it can cause muscle breakdown and low platelet counts.

The safety notes advise against high-dose niacin in pregnancy unless prescribed; normal prenatal vitamin amounts are fine. Vitamin C is generally well tolerated but very high doses can cause stomach cramps, diarrhea, kidney stones (in people at risk), and rare kidney problems.

It's considered likely safe in pregnancy at normal amounts but possibly unsafe at high doses; normal amounts while breastfeeding are fine, but avoid high-dose supplements. Ribose is generally well tolerated for up to a month but can lower blood sugar, causing dizziness or hypoglycemia, and may cause diarrhea, nausea, or headache.

Pregnancy safety data is lacking, so ribose should be avoided; the same applies to breastfeeding. Nickel (from Nicotinamide Ascorbate) is a common allergen and can cause contact dermatitis; at high doses it poses serious risks.

Pregnancy and breastfeeding safety is not established, so nickel supplements are not recommended.

Side effects, ingredient by ingredient Niacin Vitamin C Ribose Nickel

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 4 of the 4 matched ingredients can interact with medications — Ribose, Niacin, Vitamin C, Nickel.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; cancer treatments; diabetes medications.
  • For scale: 802 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking NAD+ Activate, check with your pharmacist if you take diabetes medications (including insulin), blood pressure drugs, blood thinners or antiplatelet drugs, liver-damaging medications, gout medications, statins, bile acid sequestrants, estrogen-containing birth control or hormone therapy, warfarin, levothyroxine, or certain chemotherapy drugs. These are the main drug types where documented interactions exist.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glancePartially disclosed formula with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

This product works best if you need niacin for vitamin B3 deficiency or support for abnormal cholesterol. But if you take diabetes medications, blood pressure drugs, blood thinners, thyroid medication, or estrogen-based birth control, you should check your specific medications with our tool first — niacin and vitamin C both interact with these and others.

Talk to your pharmacist before starting, especially if you have liver problems, gout, or are pregnant or breastfeeding.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 4 of 4 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jul 25, 2024.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about NAD+ Activate, straight from the product label.

Brand DaVinci Laboratories
Barcode (UPC) 026664018069
Net contents 30 Capsule(s)
Market status On market
Date entered into DSLD Jul 25, 2024
DSLD ID 313227
Product type Other Combinations
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegetarian, Adult (18 - 50 Years), Gluten Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for NAD+ Activate by DaVinci Laboratories, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
Servings per container
30
UPC/BARCODE
026664018069
IngredientAmount% DV
Niacin67.5 mg422%
Vitamin C218 mg242%
Ribose0 NP--
Bioenergy RiaGev-WS750 mg--
Nicotinamide Ascorbate0 NP--

Other ingredients: Hypromellose, Microcrystalline Cellulose, Leucine

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formulation

Color of this product may vary due to color variations of the natural ingredients.

A dietary supplement to support cellular energy

Vegetarian

Gluten free Soy free

Precautions

Warning: If pregnant or nursing, consult your healthcare practitioner before taking this product.

Keep out of reach of children.

To obtain product information or report a serious adverse event, call 1-800-325-1776

Storage

Store in a cool, dry place.

Brand IP Statement(s)

Bioenergy RiaGev-WS is a registered trademark of Bioenergy Life Science, Inc.

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Suggested/Recommended/Usage/Directions

Suggested use: As a dietary supplement take 1 capsule daily, or as directed by your healthcare practitioner.

FDA Statement of Identity

A Dietary Supplement to support cellular energy

Is this label outdated? Report a formula or label change and our pharmacy team will review it.

See for yourself

NAD+ Activate by DaVinci Laboratories label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

NAD+ Activate label

Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.

View the full label (PDF)
What’s inside

The Ingredients in NAD+ Activate by DaVinci Laboratories

These are the 4 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Servings per container30 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Niacin

Interacts with
727 drugs
67.5 mg per serving

Niacin (vitamin B3) is an essential nutrient your body needs for energy and metabolism, and deficiency is uncommon in most developed countries. Prescr...

Niacin monograph & interactions

Vitamin C

Interacts with
207 drugs
218 mg per serving

Vitamin C (ascorbic acid) is an essential nutrient your body needs but cannot make, so you must get it from food or supplements. It's important for im...

Vitamin C monograph & interactions

Bioenergy RiaGev-WS

750 mg per serving

Other (inactive) ingredients: Hypromellose, Microcrystalline Cellulose, Leucine. These complete the product’s ingredient list but are not active constituents.

Interaction report

NAD+ Activate by DaVinci Laboratories Drug Interactions

Want to check YOUR meds against NAD+ Activate?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

 Go to the checker
801Drugs
797 Moderate 4 Minor

Ingredients driving the most interactions

Niacin 727
Vitamin C 207
Ribose 86
Nicotinamide Ascorbate 1

Individual Drug Interactions

The ingredients in NAD+ Activate interact with 801 drugs. Click any drug to see the details.

4 of the 4 ingredients in NAD+ Activate interact with drugs. Each result below shows which ingredient is responsible. Niacin Vitamin C Ribose Nicotinamide Ascorbate

Each ingredient & the kinds of drugs it affects

For each ingredient in NAD+ Activate with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Niacin15 drug types · 727 drugs

Alcohol (Ethanol)

Concomitant use of alcohol and niacin might increase the risk of flushing and hepatotoxicity.
Alcohol can exacerbate the flushing and pruritus associated with niacin. Large doses of niacin might also exacerbate liver dysfunction associated with chronic alcohol use. A case report describes delirium and lactic acidosis in a patient taking niacin 3 grams daily who ingested 1 liter of wine. Advise patients to avoid large amounts of alcohol while taking niacin.

Likelihood Probable Evidence D
Allopurinol (Zyloprim)

Theoretically, niacin might antagonize the therapeutic effects of uricosurics such as allopurinol.
Large doses of niacin can reduce urinary excretion of uric acid, potentially resulting in hyperuricemia. Doses of uricosurics such as allopurinol might need to be increased to maintain control of gout in patients who start taking niacin. People who have frequent attacks of gout despite uricosuric therapy should avoid niacin.

Likelihood Probable Evidence C
Anticoagulant/Antiplatelet Drugs

Theoretically, niacin may have additive effects when used with anticoagulant or antiplatelet drugs.
Several cases of clotting factor synthesis deficiency and coagulopathy have been reported in patients taking sustained-release niacin. Also, thrombocytopenia has been reported in patients treated with niacin or niacin plus lovastatin.

Likelihood Possible Evidence D
Antidiabetes Drugs

Niacin can increase blood glucose levels and may diminish the effects of antidiabetes drugs.
Niacin impairs glucose tolerance in a dose-dependent manner, probably by causing or aggravating insulin resistance and increasing hepatic production of glucose. In diabetes patients, niacin 4.5 grams daily for 5 weeks can increase plasma glucose by an average of 16% and glycated hemoglobin (HbA1c) by 21%. However, lower doses of 1.5 grams daily or less appear to have minimal effects on blood glucose. In some patients, glucose levels increase when niacin is started, but then return to baseline when a stable dose is reached. Up to 35% of patients with diabetes may need adjustments in hypoglycemic therapy when niacin is added.

Likelihood Probable Evidence B
Antihypertensive Drugs

Theoretically, niacin may increase the risk of hypotension when used with antihypertensive drugs.
The vasodilating effects of niacin can cause hypotension. Furthermore, some clinical evidence suggests that a one-hour infusion of niacin can reduce systolic, diastolic, and mean blood pressure in hypertensive patients. This effect is not observed in normotensive patients.

Likelihood Possible Evidence B
Bile Acid Sequestrants

Bile acid sequestrants can bind niacin and decrease absorption. Separate administration by 4-6 hours to avoid an interaction.
In vitro studies show that colestipol (Colestid) binds about 98% of available niacin and cholestyramine (Questran) binds 10% to 30%.

Likelihood Possible Evidence D
Gemfibrozil (Lopid)

Theoretically, concomitant use of niacin and gemfibrozil might increase the risk of myopathy in some patients.
A case of myopathy from concomitant use of niacin and gemfibrozil has been reported. Niacin alone has also been associated with cases of myopathy. Using gemfibrozil with niacin might further increase the risk of developing myopathy.

Likelihood Possible Evidence D
Hepatotoxic Drugs

Theoretically, concomitant use of niacin and hepatotoxic drugs might increase the risk of hepatotoxicity.
Niacin has been associated with cases of liver toxicity, especially when used in pharmacologic doses. Sustained-release niacin preparations appear to be associated with a higher risk of hepatotoxicity than immediate-release niacin.

Likelihood Possible Evidence D
Hmg-Coa Reductase Inhibitors ("Statins")

Theoretically, concomitant use of niacin and statins might increase the risk of myopathy and rhabdomyolysis in some patients.
Some case reports have raised concerns that niacin might increase the risk of myopathy and rhabdomyolysis when combined with statins. However, a significantly increased risk of myopathy has not been demonstrated in clinical trials, including those using an FDA-approved combination of lovastatin and niacin (Advicor).

Likelihood Possible Evidence D
Probenecid (Benemid)

Theoretically, niacin might antagonize the therapeutic effects of uricosurics such as probenecid.
Large doses of niacin reduce urinary excretion of uric acid, potentially causing hyperuricemia. Doses of uricosurics such as probenecid might need to be increased to maintain control of gout in patients who start taking niacin. People who have frequent attacks of gout despite uricosuric therapy should avoid niacin.

Likelihood Probable Evidence C
Sulfinpyrazone (Anturane)

Theoretically, niacin might antagonize the therapeutic effects of uricosurics such as sulfinpyrazone.
Large doses of niacin reduce urinary excretion of uric acid, potentially causing hyperuricemia. Doses of uricosurics such as sulfinpyrazone might need to be increased to maintain control of gout in patients who start taking niacin. People who have frequent attacks of gout despite uricosuric therapy should avoid niacin.

Likelihood Probable Evidence C
Thyroid Hormone

Theoretically, niacin might antagonize the therapeutic effects of thyroid hormones.
Clinical research and case reports suggests that taking niacin can reduce serum levels of thyroxine-binding globulin by up to 25% and moderately reduce levels of thyroxine (T4). Patients taking thyroid hormone for hypothyroidism might need dose adjustments when using niacin.

Likelihood Probable Evidence D
Transdermal Nicotine (Nicoderm)

Theoretically, concomitant use of niacin and transdermal nicotine might increase the risk of flushing and dizziness.
Niacin and nicotine can both cause flushing and dizziness.

Likelihood Possible Evidence D
Warfarin (Coumadin)

There is limited evidence that niacin may increase the anticoagulant effects of warfarin.
In a case report, a patient on warfarin developed an elevated international normalized ratio (INR) of 3.9 after taking niacin for two weeks. The patient's INR was previously stable, ranging between 2 and 3 in recent months, and no other medication changes were identified. The elevated INR returned to therapeutic range within 4 days following the discontinuation of niacin.

Likelihood Possible Evidence D
Aspirin

Large doses of aspirin might alter the clearance of niacin.
Aspirin is often used with niacin to reduce niacin-induced flushing. Doses of 80-975 mg aspirin have been used, but 325 mg appears to be optimal. Aspirin also seems to reduce the clearance of niacin by competing for glycine conjugation. Taking aspirin 1 gram seems to reduce niacin clearance by 45%. This is probably a dose-related effect and not clinically significant with the more common aspirin dose of 325 mg.

Likelihood Likely Evidence B
Niacin full monograph & interactions

Vitamin C13 drug types · 207 drugs

Alkylating Agents

Theoretically, antioxidant effects of vitamin C might reduce the effectiveness of alkylating agents.
The use of antioxidants like vitamin C during chemotherapy is controversial. There is concern that antioxidants could reduce the activity of chemotherapy drugs that generate free radicals, such as cyclophosphamide, chlorambucil, carmustine, busulfan, and thiotepa. In contrast, some researchers theorize that antioxidants might make chemotherapy more effective by reducing oxidative stress that could interfere with apoptosis (cell death) of cancer cells. More evidence is needed to determine what effect, if any, antioxidants such as vitamin C have on chemotherapy.

Likelihood Possible Evidence D
Aluminum

Vitamin C can increase the amount of aluminum absorbed from aluminum compounds.
Research in animals and humans shows that vitamin C increases aluminum absorption, theoretically by chelating aluminum and keeping it in solution where it is available for absorption. In people with normal renal function, urinary excretion of aluminum will likely increase, making aluminum retention and toxicity unlikely. Patients with renal failure who take aluminum-containing compounds such as phosphate binders should avoid vitamin C supplements in doses above the recommended dietary allowances.

Likelihood Probable Evidence B
Antitumor Antibiotics

Theoretically, the antioxidant effects of vitamin C might reduce the effectiveness of antitumor antibiotics.
The use of antioxidants like vitamin C during chemotherapy is controversial. There is concern that antioxidants could reduce the activity of chemotherapy drugs which generate free radicals, such as doxorubicin. In contrast, some researchers theorize that antioxidants might make chemotherapy more effective by reducing oxidative stress that could interfere with apoptosis (cell death) of cancer cells. More evidence is needed to determine what effects, if any, antioxidants such as vitamin C have on chemotherapy.

Likelihood Possible Evidence D
Estrogens

Vitamin C might increase blood levels of estrogens.
Increases in plasma estrogen levels of up to 55% occur under some circumstances when vitamin C is taken concurrently with oral contraceptives or hormone replacement therapy, including topical products. It is suggested that vitamin C prevents oxidation of estrogen in the tissues, regenerates oxidized estrogen, and reduces sulfate conjugation of estrogen in the gut wall. When tissue levels of vitamin C are high, these processes are already maximized and supplemental vitamin C does not have any effect on estrogen levels. Increases in plasma estrogen levels may occur when patients who are deficient in vitamin C take supplements. Monitor these patients for estrogen-related side effects.

Likelihood Probable Evidence B
Fluphenazine (Prolixin)

Theoretically, vitamin C might decrease levels of fluphenazine.
In one patient there was a clinically significant decrease in fluphenazine levels when vitamin C (500 mg twice daily) was started. The mechanism is not known, and there is no further data to confirm this interaction.

Likelihood Possible Evidence D
Indinavir (Crixivan)

Vitamin C can modestly reduce indinavir levels.
One pharmacokinetic study shows that taking vitamin C 1 gram orally once daily along with indinavir 800 mg orally three times daily reduces the area under the concentration-time curve of indinavir by 14%. The mechanism of this interaction is unknown, but it is unlikely to be clinically significant in most patients. The effect of higher doses of vitamin C on indinavir levels is unknown.

Likelihood Probable Evidence B
Levothyroxine (Synthroid, Others)

Vitamin C can increase levothyroxine absorption.
Two clinical studies in adults with poorly controlled hypothyroidism show that swallowing levothyroxine with a glass of water containing vitamin C 500-1000 mg in solution reduces thyroid stimulating hormone (TSH) levels and increases thyroxine (T4) levels when compared with taking levothyroxine alone. This suggests that vitamin C increases the oral absorption of levothyroxine, possibly due to a reduction in pH.

Likelihood Probable Evidence B
Warfarin (Coumadin)

High-dose vitamin C might reduce the levels and effectiveness of warfarin.
Vitamin C in high doses may cause diarrhea and possibly reduce warfarin absorption. There are reports of two people who took up to 16 grams daily of vitamin C and had a reduction in prothrombin time. Lower doses of 5-10 grams daily can also reduce warfarin absorption. In many cases, this does not seem to be clinically significant. However, a case of warfarin resistance has been reported for a patient who took vitamin C 500 mg twice daily. Cessation of vitamin C supplementation resulted in a rapid increase in international normalized ratio (INR). Tell patients taking warfarin to avoid taking vitamin C in excessively high doses (greater than 10 grams daily). Lower doses may be safe, but the anticoagulation activity of warfarin should be monitored. Patients who are stabilized on warfarin while taking vitamin C should avoid adjusting vitamin C dosage to prevent the possibility of warfarin resistance.

Likelihood Possible Evidence D
Acetaminophen (Tylenol, Others)

High-dose vitamin C might slightly prolong the clearance of acetaminophen.
A small pharmacokinetic study in healthy volunteers shows that taking high-dose vitamin C (3 grams) 1.5 hours after taking acetaminophen 1 gram slightly increases the apparent half-life of acetaminophen from around 2.3 hours to 3.1 hours. Ascorbic acid competitively inhibits sulfate conjugation of acetaminophen. However, to compensate, elimination of acetaminophen glucuronide and unconjugated acetaminophen increases. This effect is not likely to be clinically significant.

Likelihood Probable Evidence B
Aspirin

Acidification of the urine by vitamin C might increase aspirin levels.
It has been suggested that acidification of the urine by vitamin C could increase reabsorption of salicylates by the renal tubules, and increase plasma salicylate levels. However, short-term use of up to 6 grams daily of vitamin C does not seem to affect urinary pH or salicylate excretion, suggesting this interaction is not clinically significant.

Likelihood Possible Evidence B
Choline Magnesium Trisalicylate (Trilisate)

Acidification of the urine by vitamin C might increase choline magnesium trisalicylate levels.
It has been suggested that acidification of the urine by vitamin C could increase reabsorption of salicylates by the renal tubules, and increase plasma salicylate levels. However, short-term use of up to 6 grams daily of vitamin C does not seem to affect urinary pH or salicylate excretion, suggesting this interaction probably is not clinically significant.

Likelihood Possible Evidence B
Niacin

Vitamin C might decrease the beneficial effects of niacin on high-density lipoprotein (HDL) cholesterol levels.
A combination of niacin and simvastatin (Zocor) effectively raises HDL cholesterol levels in patients with coronary disease and low HDL levels. Clinical research shows that taking a combination of antioxidants (vitamin C, vitamin E, beta-carotene, and selenium) along with niacin and simvastatin (Zocor) attenuates this rise in HDL, specifically the HDL-2 and apolipoprotein A1 fractions, by more than 50% in patients with coronary disease. It is not known whether this adverse effect is due to a single antioxidant such as vitamin C, or to the combination. It also is not known whether it will occur in other patient populations.

Likelihood Possible Evidence A
Salsalate (Disalcid)

Acidification of the urine by vitamin C might increase salsalate levels.
It has been suggested that acidification of the urine by vitamin C could increase reabsorption of salicylates by the renal tubules, and increase plasma salicylate levels. However, short-term use of up to 6 grams/day vitamin C does not seem to affect urinary pH or salicylate excretion, suggesting this interaction probably is not clinically significant.

Likelihood Possible Evidence B
Vitamin C full monograph & interactions

Ribose2 drug types · 86 drugs

Antidiabetes Drugs

Theoretically, taking ribose in combination with antidiabetes drugs might increase the risk of hypoglycemia.
In clinical research, ribose decreases serum glucose levels in a dose-dependent manner.

Likelihood Probable Evidence B
Insulin

Theoretically, taking ribose with insulin could increase the hypoglycemic effect of insulin.
In clinical pharmacokinetic studies, oral administration of ribose modestly increased serum insulin levels.

Likelihood Possible Evidence B
Ribose full monograph & interactions

Nicotinamide Ascorbate1 drug type · 1 drug

Disulfiram (Antabuse)

Disulfiram can reduce the absorption and clinical effects of nickel.
Disulfiram can chelate nickel, preventing its absorption. This interaction has been used therapeutically to reduce eczema in people with severe nickel hypersensitivity.

Likelihood Probable Evidence B
Nicotinamide Ascorbate full monograph & interactions
The maker

Brand information

Manufacturer and brand details for NAD+ Activate, from the product label.

DaVinci Laboratories

See all DaVinci Laboratories products
Name
DaVinci Laboratories a division of FoodScience LLC
Street Address
929 Harvest Lane
City
Williston
State
VT
ZipCode
05495
Phone Number
1-800-325-1776
Web Address
www.davincilabs.com
Pharmacist Counseling Corner

NAD+ Activate by DaVinci Laboratories: Common Questions

Does NAD+ Activate by DaVinci Laboratories interact with any medications?
Yes. Based on its ingredients, NAD+ Activate has a known interaction with 801 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
NAD+ Activate contains 4 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is this safe to take if I'm pregnant?
The niacin in this product is likely safe at normal prenatal vitamin doses, but high-dose niacin should be avoided unless your doctor prescribes it. Ribose and nickel supplements are not recommended in pregnancy because safety data is insufficient. Talk with your doctor or pharmacist before taking this product if you're pregnant.
Can I take this if I'm breastfeeding?
Normal amounts of niacin and vitamin C from food and standard supplements are generally fine while breastfeeding. However, ribose and nickel supplements should be avoided because there isn't enough safety information. Ask your pharmacist before starting.
What's the niacin flushing I've heard about?
Niacin commonly causes flushing — a warm, red, tingling feeling on your face and upper body — in up to 70% of people taking therapeutic doses. It's a temporary reaction from blood vessel dilation and usually goes away within two weeks as your body adjusts. Taking it with food or an antacid may help.
Could ribose lower my blood sugar?
Yes. Ribose can lower blood glucose levels, so if you take diabetes medications or insulin, there's a theoretical risk of low blood sugar. The product facts also note that common side effects can include low blood sugar symptoms like dizziness and lightheadedness. Ask your doctor or pharmacist before taking this if you have diabetes.
What does each ingredient in this product do?
Niacin supports energy metabolism and cellular repair. Vitamin C is an antioxidant for immune support. Ribose is a sugar that helps your cells make energy. Nicotinamide Ascorbate supplies nickel (though nickel supplements are generally not recommended because it's a common allergen). Bioenergy RiaGev-WS is a proprietary blend whose specific role isn't detailed in the product facts.
Is NAD+ Activate effective for fatigue or energy?
The ingredients in this product are involved in energy metabolism, but the product facts don't include effectiveness evidence specifically for fatigue or general energy. The evidence we hold covers niacin for B3 deficiency and certain cholesterol conditions, and vitamin C for specific deficiencies — not general energy support. Talk with your pharmacist about whether this matches your health goal.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if NAD+ Activate is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

NAD+ Activate label
Go deeper

The Full Monographs Behind NAD+ Activate’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Niacin

Interacts with 727 drugs

Niacin (vitamin B3) is an essential nutrient your body needs for energy and metabolism, and deficiency is uncommon in most developed countries. Prescription-strength niacin has been used to...

Read the full Niacin monograph → Herb & supplement monograph

Vitamin C

Interacts with 207 drugs

Vitamin C (ascorbic acid) is an essential nutrient your body needs but cannot make, so you must get it from food or supplements. It's important for immune function, collagen, and acts as an...

Read the full Vitamin C monograph → Herb & supplement monograph

Ribose

Interacts with 86 drugs

Ribose (D-ribose) is a simple sugar your body makes naturally and uses to build energy molecules like ATP. Some people take it for fatigue, fibromyalgia, exercise recovery, or heart conditio...

Read the full Ribose monograph → Herb & supplement monograph

Nickel

Interacts with 1 drug

Nickel is a trace element found in tiny amounts in many foods, and most people get plenty through diet. There is no proven need for nickel supplements, and because nickel is a common cause o...

Read the full Nickel monograph →
Sources

Sources & How We Checked

NAD+ Activate's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 201 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Niacin 66 references
  1. Garg R, Malinow MR, Pettinger M, et al. Niacin treatment increases plasma homocysteine levels. Am Heart J 1999;138:1082-7.
  2. Anon. Inositol hexaniacinate. Altern Med Rev 1998;3:222-3.
  3. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987;2:10-32. PubMed
  4. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000;160:1177-84. PubMed
  5. Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995;99:378-85. PubMed
  6. Whelan AM, Price SO, Fowler SF, Hainer BL. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 1992;34:165-8.
  7. Jungnickel PW, Maloley PA, Vander Tuin EL, et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997;12:591-6. PubMed
  8. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82:74-81;disc. 85U-6U. PubMed
  9. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994;121:252-8. PubMed
  10. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7. DOI
  11. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-104. PubMed
  12. Knopp RH. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing. Am J Cardiol 1998;82:24U-28U;discussion 39U-41U. PubMed
  13. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723-6. DOI
  14. Leighton RF, Gordon NF, Small GS, et al. Dental and gingival pain as side effects of niacin therapy. Chest 1998;114:1472-4. PubMed
  15. American Society of Health-System Pharmacists. ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. Am J Health Syst Pharm 1997;54:2815-9. DOI
  16. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med 1994;154:73-82. DOI
  17. Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737-43.
  18. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline (2000). Washington, DC: National Academy Press, 2000. Available at: http://b
  19. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-93. DOI
  20. Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998;19:355-71. PubMed
  21. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992;92:77-81. PubMed
  22. Kahn SE, Beard JC, Schwartz MW, et al. Increased B-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989;38:562-8.
  23. Schwartz ML. Severe reversible hyperglycemia as a consequence of niacin therapy. Arch Int Med 1993;153:2050-2. DOI
  24. Raising HDL and Niacin Use. Pharmacist's Letter/Prescriber's Letter 2004;20(5):200504.
  25. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164:697-705. PubMed
  26. Reaven P, Witztum JL. Lovastatin, nicotinic acid and rhabdomyolysis (letter). Ann Int Med 1988;109:597-8. PubMed
  27. Ito MK. Advances in the understanding and management of dyslipidemia: using niacin-based therapies. Am J Health-Syst Pharm 2003;60(suppl 2):s15-21. PubMed
  28. Schwab RA, Bachhuber BH. Delirium and lactic acidosis caused by ethanol and niacin coingestion. Am J Emerg Med 1991;9:363-5. PubMed
  29. Product information: Niaspan. Kos Pharmaceuticals. Cranbury, NJ. 2005. Available at www.niaspan.com/professional/content/pdfs/productinfo.pdf. (Accessed 3 March 2006).
  30. Ding RW, Kolbe K, Merz B, et al. Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther 1989;46:642-7. PubMed
  31. NIH News. NIH stops clinical trial on combination cholesterol treatment. May 26, 2011. http://www.nih.gov/news/health/may2011/nhlbi-26.htm. (Accessed 3 June 2011).
  32. Dearing BD, Lavie CJ, Lohmann TP, Genton E. Niacin-induced clotting factor synthesis deficiency with coagulopathy. Arch Intern Med. 1992;152(4):861-3. DOI
  33. O'Brien T, Silverberg JD, Nguyen TT. Nicotinic acid-induced toxicity associated with cytopenia and decreased levels of thyroxine-binding globulin. Mayo Clin Proc. 1992;67(5):465-8. PubMed
  34. Gadegbeku CA, Dhandayuthapani A, Shrayyef MZ, Egan BM. Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects. Am J Hypertens. 2003;16(1):67-71. PubMed
  35. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm. 1995;52(15):1639-45. PubMed
  36. Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med. 1989;86(4):481-3. PubMed
  37. Dunn RT, Ford MA, Rindone JP, Kwiecinski FA. Low-Dose Aspirin and Ibuprofen Reduce the Cutaneous Reactions Following Niacin Administration. Am J Ther. 1995;2(7):478-480. PubMed
  38. Cashin-Hemphill L, Spencer CA, Nicoloff JT, et al. Alterations in serum thyroid hormonal indices with colestipol-niacin therapy. Ann Intern Med. 1987;107(3):324-9. PubMed
  39. Drinka PJ. Alterations in thyroid and hepatic function tests associated with preparations of sustained-release niacin. Mayo Clin Proc. 1992;67(12):1206. PubMed
  40. Shakir KM, Kroll S, Aprill BS, Drake AJ 3rd, Eisold JF. Nicotinic acid decreases serum thyroid hormone levels while maintaining a euthyroid state. Mayo Clin Proc. 1995;70(6):556-8. PubMed
  41. Etchason JA, Miller TD, Squires RW, et al. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proc. 1991;66(1):23-8. PubMed
  42. Henkin Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. JAMA. 1990;264(2):241-3. DOI
  43. Henkin Y, Oberman A, Hurst DC, Segrest JP. Niacin revisited: clinical observations on an important but underutilized drug. Am J Med. 1991;91(3):239-46. PubMed
  44. Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80(2)
  45. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 2000;85(9):1100-5. PubMed
  46. Aronov DM, Keenan JM, Akhmedzhanov NM, et al. Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia. Arch Fam Med. 1996;5(10):567-75. PubMed
  47. Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial. J Cardiovasc Pharmacol Ther. 1996;1(3):195-202. PubMed
  48. Andersson RG, Aberg G, Brattsand R, Ericsson E, Lundholm L. Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol Toxicol (Copenh). 1977 Jul;41(1):1-10. PubMed
  49. Brown WV. Niacin for lipid disorders. Indications, effectiveness, and safety. Postgrad Med. 1995 Aug;98(2):185-9, 192-3. PubMed
  50. O'REILLY PO, CALLBECK MJ, HOFFER A. Sustained-release nicotinic acid (nicospan); effect on (1) cholesterol levels and (2) leukocytes. Can Med Assoc J. 1959;80(5):359-62.
  51. Gharavi AG, Diamond JA, Smith DA, Phillips RA. Niacin-induced myopathy. Am J Cardiol. 1994;74(8):841-2. PubMed
  52. Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med. 1989;86(4):481-3. PubMed
  53. Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol 1995;79:54-56. PubMed
  54. Ali EH, McJunkin B, Jubelirer S, Hood W. Niacin induced coagulopathy as a manifestation of occult liver injury. W V Med J. 2013 Jan-Feb;109(1):12-4
  55. Aramwit P, Srisawadwong R, Supasyndh O. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients. J Nephrol. 2012 May-Jun;25(3):354-62. PubMed
  56. Bassan M. A case for immediate-release niacin. Heart Lung. 2012 Jan-Feb;41(1):95-8. PubMed
  57. Davidson MH, Rooney M, Pollock E, Drucker J, Choy Y. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. J Clin Lipidol. 2013 Sep-Oct;7(5):423-32. PubMed
  58. Guyton JR, Fazio S, Adewale AJ, Jensen E, Tomassini JE, Shah A, Tershakovec AM. Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. Diabetes Care. 2012 PubMed
  59. Loebl T, Raskin S. A novel case report: acute manic psychotic episode after treatment with niacin. J Neuropsychiatry Clin Neurosci. 2013 Fall;25(4):E14. PubMed
  60. Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE; AIM-HIGH Investigators. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the
  61. Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomized controlled trials. Heart. 2016 Feb;102(3):198-203.
  62. Schandelmaier S, Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, Nordmann AJ. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2017 Jun 14;6:CD009744. PubMed
  63. Jenkins DJA, Spence JD, Giovannucci EL, et al. Supplemental vitamins and minerals for CVD prevention and treatment. J Am Coll Cardiol 2018;71(22):2570-84. PubMed
  64. Song S, Lee CJ, Oh J, Park S, Kang SM, Lee SH. Effect of Niacin on Carotid Atherosclerosis in Patients at Low-Density Lipoprotein-Cholesterol Goal but High Lipoprotein (a) Level: a 2-Year Follow-Up Study. J Lipid Atheroscler. 2019;8(1):58-66. PubMed
  65. Kimura H, Umemori Y, Yuki D. Anaphylactic shock-like symptoms due to niacin overdose: A case report. J Dermatol 2022;49(8):e287-e288. PubMed
  66. Nawaz N, Mistretta T, Karime C, Lewis J, Wolf E. Cholestatic Drug-Induced Liver Injury in a Patient Taking High-Dose Niacin for Hyperlipidemia. J Investig Med High Impact Case Rep 2024;12:23247096231224349. PubMed

See these in context on the Niacin monograph →

Vitamin C 51 references
  1. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
  2. Back DJ, Breckenridge AM, MacIver M, et al. Interaction of ethinyloestradiol with ascorbic acid in man. Br Med J (Clin Res Ed) 1981;282:1516.
  3. Morris JC, Beeley L, Ballantine N. Interaction of ethinyloestradiol with ascorbic acid in man [letter]. Br Med J (Clin Res Ed) 1981;283:503.
  4. Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology 1999;13:1003-8.
  5. Dwyer JH, Merz NB, Shirocre AM, et al. Progression of early atherosclerosis and intake of vitamin C and vitamin E from supplements and food. The Los Angeles Atherosclerosis Study. 41st Annual Conference on Cardiovascular Disease Epidemiology and Prevent
  6. Levine M, Rumsey SC, Daruwala R, et al. Criteria and recommendations for vitamin C intake. JAMA 1999;281:1415-23. PubMed
  7. Hansten PD, Horn JR. Drug Interactions Analysis and Management. Vancouver, WA: Applied Therapeutics Inc., 1997 and updates.
  8. Segal S, Kaminski S. Drug-nutrient interactions. American Druggist 1996 Jul;42-8.
  9. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: National Academy Press, 2000. Available at: http://www.nap.edu/books/0309069351/html/.
  10. Houston JB, Levy G. Drug biotransformation interactions in man VI: Acetaminophen and ascorbic acid. J Pharm Sci 1976;65:1218-21. PubMed
  11. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-93. DOI
  12. Rosenthal G. Interaction of ascorbic acid and warfarin. JAMA 1971;215:1671. DOI
  13. Hume R, Johnstone JM, Weyers E. Interaction of ascorbic acid and warfarin. JAMA 1972;219:1479. DOI
  14. Smith EC, Skalski RJ, Johnson GC, Rossi GV. Interaction of ascorbic acid and warfarin. JAMA 1972;221:1166. DOI
  15. Traxer O, Huet B, Poindexter J, et al. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003;170:397-401.. PubMed
  16. Domingo JL, Gomez M, Llobet JM, Richart C. Effect of ascorbic acid on gastrointestinal aluminum absorption (letter). Lancet 1991;338:1467.
  17. Domingo JL, Gomez M, Llobet JM, Corbella J. Influence of some dietary constituents on aluminum absorption and retention in rats. Kidney Int 1991;39:598-601. PubMed
  18. Partridge NA, Regnier FE, White JL, Hem SL. Influence of dietary constituents on intestinal absorption of aluminum. Kidney Int 1989;35:1413-7. PubMed
  19. Mc Leod DC, Nahata MC. Inefficacy of ascorbic acid as a urinary acidifier (letter). N Engl J Med 1977;296:1413. DOI
  20. Hansten PD, Hayton WL. Effect of antacid and ascorbic acid on serum salicylate concentration. J Clin Pharmacol 1980;20:326-31. PubMed
  21. Dysken MW, Cumming RJ, Channon RA, Davis JM. Drug interaction between ascorbic acid and fluphenazine. JAMA 1979;241:2008. DOI
  22. Vihtamaki T, Parantainen J, Koivisto AM, et al. Oral ascorbic acid increases plasma oestradiol during postmenopausal hormone replacement therapy. Maturitas 2002;42:129-35. PubMed
  23. Slain D, Amsden JR, Khakoo RA, et al. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Pharmacotherapy 2005;25:165-70. PubMed
  24. Cheung MC, Zhao XQ, Chait A, et al. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001;21:1320-6. PubMed
  25. Feetam CL, Leach RH, Meynell MJ. Lack of a clinically important interaction between warfarin and ascorbic acid. Toxicol Appl Pharmacol 1975;31:544-7. PubMed
  26. Weintraub M, Griner PF. Warfarin and ascorbic acid: lack of evidence for a drug interaction. Toxicol Appl Pharmacol 1974;28:53-6. PubMed
  27. Lee DH, Folsom AR, Harnack L, et al. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr 2004;80:1194-200. PubMed
  28. Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004;15:3225-32. PubMed
  29. Ward NC, Hodgson JM, Croft KD, et al. The combination of vitamin C and grape-seed polyphenols increases blood pressure: a randomized, double-blind, placebo-controlled trial. J Hypertens 2005;23:427-34.. PubMed
  30. Prasad KN. Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy. J Nutr 2004;134:3182S-3S. PubMed
  31. Conklin KA. Cancer chemotherapy and antioxidants. J Nutr 2004;134:3201S-3204S. PubMed
  32. Fairweather-Tait S, Hickson K, McGaw B, et al. Orange juice enhances aluminium absorption from antacid preparation. Eur J Clin Nutr. 1994;48(1):71-3.
  33. Gruenwald, J., Graubaum, H. J., Busch, R., and Bentley, C. Safety and tolerance of ester-C compared with regular ascorbic acid. Adv.Ther. 2006;23(1):171-178.
  34. Rahimi, R., Nikfar, S., Rezaie, A., and Abdollahi, M. A meta-analysis on the efficacy and safety of combined vitamin C and E supplementation in preeclamptic women. Hypertens.Pregnancy. 2009;28(4):417-434. PubMed
  35. Einerson, B., Nathorn, C., Kitiyakara, C., Sirada, M., and Thamlikitkul, V. The efficacy of ascorbic acid in suboptimal responsive anemic hemodialysis patients receiving erythropoietin: a meta-analysis. J Med.Assoc.Thai. 2011;94 Suppl 1:S134-S146.
  36. Li, G., Li, L., Yu, C., and Chen, L. Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis. Br.J Nutr 2011;106(11):1632-1637.
  37. Chen X, Shen L, Gu X, et al. High-dose supplementation with vitamin C--induced pediatric urolithiasis: the first case report in a child and literature review. Urology. 2014;84(4):922-4. PubMed
  38. Sattar A, Willman JE, Kolluri R. Possible warfarin resistance due to interaction with ascorbic acid: case report and literature review. Am J Health Syst Pharm. 2013;70(9):782-6. PubMed
  39. Yaich S, Chaabouni Y, Charfeddine K, et al. Secondary oxalosis due to excess vitamin C intake: a cause of graft loss in a renal transplant recipient. Saudi J Kidney Dis Transpl. 2014;25(1):113-6. PubMed
  40. Jalloh MA, Gregory PJ, Hein D, et al. Dietary supplement interactions with antiretrovirals: a systematic review. Int J STD AIDS. 2017 Jan;28(1):4-15. PubMed
  41. Rumbold A, Ota E, Nagata C, Shahrook S, Crowther CA. Vitamin C supplementation in pregnancy. Cochrane Database Syst Rev. 2015;(9):CD004072. PubMed
  42. Seo MS, Kim JK, Shim JY. High-dose vitamin C promotes regression of multiple pulmonary metastases originating from hepatocellular carcinoma. Yonsei Med J. 2015;56(5):1449-52. PubMed
  43. Skelin M, Lucijanic T, Amidzic Klaric D, et al. Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review. Clin Ther. 2017 Feb;39(2):378-403. PubMed
  44. Jiang K, Tang K, Liu H, Xu H, Ye Z, Chen Z. Ascorbic acid supplements and kidney stones incidence among men and women: a systematic review and meta-analysis. Urol J. 2019;16(2):115-120.
  45. Thomas S, Patel D, Bittel B, et al. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial. JAMA Netw Open. 2 PubMed
  46. Giffen MA, McLemore JL. Hyperoxalosis Secondary to Intravenous Vitamin C Administration as a Non-Allopathic Treatment for Cancer. Acad Forensic Pathol 2019;9(1-2):118-126. PubMed
  47. Maike A, Sturgill D, Gallan A. Oxalate Nephropathy in a Renal Transplant Recipient After Receiving High Dose Ascorbic Acid. Am J Med Sci 2021. PubMed
  48. Shen ZY, Chen YR, Wang MC, Chang SS. High-dose vitamin C-induced acute oxalate nephropathy in a renal transplant recipient: a case report and literature review. Asian J Surg 2022. PubMed
  49. Yanase F, Spano S, Maeda A, et al. Mega-dose sodium ascorbate: a pilot, single-dose, physiological effect, double-blind, randomized, controlled trial. Crit Care 2023;27(1):371. PubMed
  50. Sharma Y, Sumanadasa S, Shahi R, et al. Efficacy and safety of vitamin C supplementation in the treatment of community-acquired pneumonia: a systematic review and meta-analysis with trial sequential analysis. Sci Rep 2024;14(1):11846. PubMed
  51. Pejcic AV, Petrovic NZ, Djordjic MD, Milosavljevic MN. Vitamin C Levels in Pregnant Women and the Efficacy of Vitamin C Supplements in Preventing Premature Rupture of Membranes: A Systematic Review and Meta-Analysis. Balkan Med J 2024;41(4):248-260. PubMed

See these in context on the Vitamin C monograph →

Ribose 8 references
  1. Segal S, Foley J. The metabolism of D-ribose in man. J Clin Invest 1958;37:719-35. PubMed
  2. Perlmutter NS, Wilson RA, Angello DA, et al. Ribose facilitates thallium-201 redistribution in patients with coronary artery disease. J Nucl Med 1991;32:193-200.
  3. Hegewald MG, Palac RT, Angello DA, et al. Ribose infusion accelerates thallium redistribution with early imaging compared with late 24-hour imaging without ribose. J Am Coll Cardiol 1991;18:1671-81. PubMed
  4. Pliml W, von Arnim T, Stalein A, et al. Effects of ribose on excercise-induced ischaemia in stable coronary artery disease. Lancet 1992;340:507-10.
  5. Burke ER. D-Ribose What You Need To Know. Garden City Park, NY: Avery Publishing Group 1999;1-43.
  6. Gross M, Reiter S, Zollner N. Metabolism of D-ribose administered continuously to healthy persons and to patients with myoadenylate deaminase deficiency. Klin Wochenschr 1989;67:1205-13. PubMed
  7. Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med 2006;12:857-62. PubMed
  8. Thompson J, Neutel J, Homer K, Tempero K, Shah A, Khankari R. Evaluation of D-ribose pharmacokinetics, dose proportionality, food effect, and pharmacodynamics after oral solution administration in healthy male and female subjects. J Clin Pharmacol 2014;54 PubMed

See these in context on the Ribose monograph →

Nickel 76 references
  1. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002.
  2. Sharma AD. Disulfiram and low nickel diet in the management of hand eczema: a clinical study. Indian J Dermatol Venereol Leprol 2006;72:113-8. PubMed
  3. Denkhaus E, Salnikow K. Nickel essentiality, toxicity, and carcinogenicity. Crit Rev Oncol Hematol 2002;42:35-56. PubMed
  4. Barceloux DG. Nickel. J Toxicol Clin Toxicol 1999;37:239-58.
  5. Sunderman, F. W., Jr. Nasal toxicity, carcinogenicity, and olfactory uptake of metals. Ann.Clin.Lab Sci 2001;31(1):3-24.
  6. Hayes, R. B. The carcinogenicity of metals in humans. Cancer Causes Control 1997;8(3):371-385. PubMed
  7. Nemery, B. Metal toxicity and the respiratory tract. Eur Respir.J 1990;3(2):202-219. DOI
  8. Andersen, A., Barlow, L., Engeland, A., Kjaerheim, K., Lynge, E., and Pukkala, E. Work-related cancer in the Nordic countries. Scand.J.Work Environ.Health 1999;25 Suppl 2:1-116.
  9. Haber, L. T., Erdreicht, L., Diamond, G. L., Maier, A. M., Ratney, R., Zhao, Q., and Dourson, M. L. Hazard identification and dose response of inhaled nickel-soluble salts. Regul.Toxicol.Pharmacol. 2000;31(2 Pt 1):210-230. PubMed
  10. Kelleher, P., Pacheco, K., and Newman, L. S. Inorganic dust pneumonias: the metal-related parenchymal disorders. Environ.Health Perspect. 2000;108 Suppl 4:685-696. PubMed
  11. Seilkop, S. K. Occupational exposures and pancreatic cancer: a meta-analysis. Occup.Environ.Med. 2001;58(1):63-64. PubMed
  12. Williams, M. D. and Sandler, A. B. The epidemiology of lung cancer. Cancer Treat.Res. 2001;105:31-52. PubMed
  13. Laffargue, P., Hildebrand, H. F., Lecomte-Houcke, M., Biehl, V., Breme, J., and Decoulx, J. [Malignant fibrous histiocytoma of bone 20 years after femoral fracture treated by plate-screw fixation: analysis of corrosion products and their role in malignan
  14. Ring, J., Brockow, K., and Behrendt, H. Adverse reactions to foods. J.Chromatogr.B Biomed.Sci.Appl. 5-25-2001;756(1-2):3-10. PubMed
  15. Egedahl, R., Carpenter, M., and Lundell, D. Mortality experience among employees at a hydrometallurgical nickel refinery and fertiliser complex in Fort Saskatchewan, Alberta (1954-95). Occup.Environ.Med. 2001;58(11):711-715. PubMed
  16. Leikauf, G. D. Hazardous air pollutants and asthma. Environ.Health Perspect. 2002;110 Suppl 4:505-526. PubMed
  17. Oller, A. R. Respiratory carcinogenicity assessment of soluble nickel compounds. Environ.Health Perspect. 2002;110 Suppl 5:841-844. PubMed
  18. Kielhorn, J., Melber, C., Keller, D., and Mangelsdorf, I. Palladium--a review of exposure and effects to human health. Int.J.Hyg.Environ.Health 2002;205(6):417-432. PubMed
  19. Grimsrud, T. K., Berge, S. R., Haldorsen, T., and Andersen, A. Exposure to different forms of nickel and risk of lung cancer. Am.J.Epidemiol. 12-15-2002;156(12):1123-1132. PubMed
  20. Verougstraete, V., Lison, D., and Hotz, P. Cadmium, lung and prostate cancer: a systematic review of recent epidemiological data. J.Toxicol.Environ.Health B Crit Rev. 2003;6(3):227-255. PubMed
  21. Nikula, K. J. and Green, F. H. Animal models of chronic bronchitis and their relevance to studies of particle-induced disease. Inhal.Toxicol. 2000;12 Suppl 4:123-153. PubMed
  22. Comba, P. and Belli, S. [Etiological epidemiology of tumors of the nasal cavities and the paranasal sinuses]. Ann.Ist.Super.Sanita 1992;28(1):121-132.
  23. Sanchez-Morillas, L., Reano, Martos M., Rodriguez, Mosquera M., Iglesias, Cadarso C., Gonzalez, Sanchez L., and Dominguez Lazaro, A. R. [Baboon syndrome]. Allergol.Immunopathol.(Madr.) 2004;32(1):43-45.
  24. Coultas, D. B. and Samet, J. M. Occupational lung cancer. Clin.Chest Med. 1992;13(2):341-354. DOI
  25. Garner, L. A. Contact dermatitis to metals. Dermatol.Ther. 2004;17(4):321-327. PubMed
  26. Sorahan, T. and Williams, S. P. Mortality of workers at a nickel carbonyl refinery, 1958-2000. Occup.Environ.Med. 2005;62(2):80-85. PubMed
  27. Alberg, A. J., Brock, M. V., and Samet, J. M. Epidemiology of lung cancer: looking to the future. J.Clin.Oncol. 5-10-2005;23(14):3175-3185. PubMed
  28. Blanusa, M., Varnai, V. M., Piasek, M., and Kostial, K. Chelators as antidotes of metal toxicity: therapeutic and experimental aspects. Curr.Med.Chem. 2005;12(23):2771-2794. PubMed
  29. Grimsrud, T. K. and Peto, J. Persisting risk of nickel related lung cancer and nasal cancer among Clydach refiners. Occup.Environ.Med. 2006;63(5):365-366.
  30. Hostynek, J. J. Sensitization to nickel: etiology, epidemiology, immune reactions, prevention, and therapy. Rev.Environ.Health 2006;21(4):253-280. PubMed
  31. Das, K. K. and Buchner, V. Effect of nickel exposure on peripheral tissues: role of oxidative stress in toxicity and possible protection by ascorbic acid. Rev.Environ.Health 2007;22(2):157-173. PubMed
  32. Thyssen, J. P., Linneberg, A., Menne, T., and Johansen, J. D. The epidemiology of contact allergy in the general population--prevalence and main findings. Contact Dermatitis 2007;57(5):287-299. PubMed
  33. Czarnobilska, E., Obtulowicz, K., and Wsolek, K. [Type IV of hypersensitivity and its subtypes]. Przegl.Lek. 2007;64(7-8):506-508.
  34. Sunderman, F. W., Sr. Therapeutic properties of sodium diethyldithiocarbamate: its role as an inhibitor in the progression of AIDS. Ann.Clin.Lab Sci. 1991;21(1):70-81.
  35. Schmahl, D. [Etiology of bronchial cancer: smoking, passive smoking, environment and occupation]. Pneumologie 1991;45(4):134-136.
  36. Das, K. K., Das, S. N., and Dhundasi, S. A. Nickel, its adverse health effects & oxidative stress. Indian J.Med.Res. 2008;128(4):412-425.
  37. Bruske-Hohlfeld, I. Environmental and occupational risk factors for lung cancer. Methods Mol.Biol. 2009;472:3-23. PubMed
  38. Thyssen, J. P., Carlsen, B. C., and Menne, T. Nickel sensitization, hand eczema, and loss-of-function mutations in the filaggrin gene. Dermatitis 2008;19(6):303-307. DOI
  39. Nijhawan, R. I., Molenda, M., Zirwas, M. J., and Jacob, S. E. Systemic contact dermatitis. Dermatol.Clin. 2009;27(3):355-64, vii. PubMed
  40. Zhang, Z., Chau, P. Y., Lai, H. K., and Wong, C. M. A review of effects of particulate matter-associated nickel and vanadium species on cardiovascular and respiratory systems. Int.J.Environ.Health Res. 2009;19(3):175-185. PubMed
  41. Wataha, J. C. and Shor, K. Palladium alloys for biomedical devices. Expert.Rev.Med.Devices 2010;7(4):489-501. PubMed
  42. Garcia-Patos, V., Alomar, A., Lleonart, R., Cistero, A., and Matias-Guiu, X. [Subcutaneous nodules and sensitivity to aluminum in patients undergoing hyposensitivity immunotherapy]. Med.Cutan.Ibero.Lat.Am. 1990;18(2):83-88.
  43. van, Joost T. and Roesyanto-Mahadi, I. D. Combined sensitization to palladium and nickel. Contact Dermatitis 1990;22(4):227-228. PubMed
  44. Baur, X. [New occupational inhaled pollutants]. Pneumologie 1990;44 Suppl 1:397-398.
  45. Tossavainen, A. Estimated risk of lung cancer attributable to occupational exposures in iron and steel foundries. IARC Sci.Publ. 1990;(104):363-367.
  46. Ward, J. J., Thornbury, D. D., Lemons, J. E., and Dunham, W. K. Metal-induced sarcoma. A case report and literature review. Clin.Orthop.Relat Res. 1990;(252):299-306. DOI
  47. Sunderman, F. W., Jr. Carcinogenicity of metal alloys in orthopedic prostheses: clinical and experimental studies. Fundam.Appl.Toxicol. 1989;13(2):205-216. DOI
  48. Adachi, S. and Takemoto, K. [Occupational lung cancer. A comparison between humans and experimental animals]. Sangyo Igaku 1987;29(5):345-357. PubMed
  49. Sunderman, F. W., Jr. A review of the metabolism and toxicology of nickel. Ann.Clin.Lab Sci. 1977;7(5):377-398.
  50. Sky-Peck, H. H. Trace metals and neoplasia. Clin.Physiol Biochem. 1986;4(1):99-111.
  51. Roush, G. C. Epidemiology of cancer of the nose and paranasal sinuses: current concepts. Head Neck Surg. 1979;2(1):3-11. PubMed
  52. Bencko, V. Nickel: a review of its occupational and environmental toxicology. J.Hyg.Epidemiol.Microbiol.Immunol. 1983;27(2):237-247.
  53. Ives, J. C., Buffler, P. A., and Greenberg, S. D. Environmental associations and histopathologic patterns of carcinoma of the lung: the challenge and dilemma in epidemiologic studies. Am.Rev.Respir.Dis. 1983;128(1):195-209. PubMed
  54. Ernst, P. and Theriault, G. Known occupational carcinogens and their significance. Can.Med.Assoc.J. 4-1-1984;130(7):863-867. DOI
  55. Langard, S. and Stern, R. M. Nickel in welding fumes--a cancer hazard to welders? A review of epidemiological studies on cancer in welders. IARC Sci.Publ. 1984;(53):95-103.
  56. Langard, S. Prevention of lung cancer through the use of knowledge on asbestos and other work-related causes--Norwegian experiences. Scand.J.Work Environ.Health 1994;20 Spec No:100-107.
  57. Ruegger, M. [Lung disorders due to metals]. Schweiz.Med.Wochenschr. 3-11-1995;125(10):467-474.
  58. Wingren, G. and Axelson, O. Epidemiologic studies of occupational cancer as related to complex mixtures of trace elements in the art glass industry. Scand.J.Work Environ.Health 1993;19 Suppl 1:95-100.
  59. Shen, H. M. and Zhang, Q. F. Risk assessment of nickel carcinogenicity and occupational lung cancer. Environ.Health Perspect. 1994;102 Suppl 1:275-282. PubMed
  60. Herfs, H., Schirren, C. G., Przybilla, B., and Plewig, G. ["Baboon syndrome". A particular manifestation of hematogenous contact reaction]. Hautarzt 1993;44(7):466-469.
  61. Reger, R. B. and Morgan, W. K. Respiratory cancers in mining. Occup.Med. 1993;8(1):185-204.
  62. Kohout, J., Ouda, Z., and Hora, M. [Risk factors in carcinoma of the prostate]. Cas.Lek.Cesk. 11-1-1995;134(21):679-680.
  63. Wataha, J. C. and Hanks, C. T. Biological effects of palladium and risk of using palladium in dental casting alloys. J.Oral Rehabil. 1996;23(5):309-320. PubMed
  64. Lewis, C. G. and Sunderman, F. W., Jr. Metal carcinogenesis in total joint arthroplasty. Animal models. Clin.Orthop.Relat Res. 1996;(329 Suppl):S264-S268. PubMed
  65. Savolainen, H. Biochemical and clinical aspects of nickel toxicity. Rev.Environ.Health 1996;11(4):167-173. PubMed
  66. Moulin, J. J. A meta-analysis of epidemiologic studies of lung cancer in welders. Scand.J.Work Environ.Health 1997;23(2):104-113. PubMed
  67. Smith, C. J., Livingston, S. D., and Doolittle, D. J. An international literature survey of "IARC Group I carcinogens" reported in mainstream cigarette smoke. Food Chem.Toxicol. 1997;35(10-11):1107-1130. PubMed
  68. Di Gioacchino M, Ricciardi L, De Pità O, et al. Nickel oral hyposensitization in patients with systemic nickel allergy syndrome. Ann Med. 2014 Feb;46(1):31-7. Epub 2013 Nov 21. PubMed
  69. Delimar D, Bohacek I, Pastar Z, Lipozencic J. Orthopedic and Cutaneous Reactions to Nickel after Total Hip Replacement. Acta Dermatovenerol Croat. 2018 Apr;26(1):39-43. Review.
  70. Maridet C, Atge B, Amici JM, Taïeb A, Milpied B. The electronic cigarette: the new source of nickel contact allergy of the 21st century? Contact Dermatitis. 2015 Jul;73(1):49-50. Epub 2015 Mar 20. PubMed
  71. Dominguez-Massa C, Bel-Minguez AM, Perez-Guillen M, Berbel-Bonillo A, Hornero-Sos F. Mitral Ring Extraction due to Nickel Allergy. Ann Thorac Surg. 2018 Apr;105(4):e177-e178. Epub 2017 Dec 20. PubMed
  72. Díaz Palacios MA, López-Salgueiro R, Mencía Sanchez G, Martínez Romero A, Morales-Rubio A, Hernández Fernández de Rojas D. Chronic Urticaria After Implantation of a Mitral Annuloplasty Ring in a Nickel-Allergic Patient. J Investig Allergol Clin Immunol. 2 PubMed
  73. Alinaghi F, Bennike NH, Egeberg A, Thyssen JP, Johansen JD. Prevalence of contact allergy in the general population: A systematic review and meta-analysis. Contact Dermatitis. 2019 Feb;80(2):77-85. PubMed
  74. Shim TN, Kosztyuova T. Allergic Contact Dermatitis to Electronic Cigarette. Dermatitis. 2018 Mar/Apr;29(2):94-95. PubMed
  75. Fung E, Fong MW, Correa AJ, Yoon AJ, Grazette LP. Fulminant eosinophilic myocarditis following ICD implantation in a patient with undisclosed nickel allergy. Int J Cardiol. 2016 Jan 15;203:1018-9. PubMed
  76. Ledon JA, Tosti A. CrossFit-Associated Allergic Contact Dermatitis. Dermatitis. 2017 Nov/Dec;28(6):368. PubMed

See these in context on the Nickel monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring
Supplement interaction checker › Check any supplement or product against your medications Drug–drug interactions › Check two or more of your medications against each other Browse medications A–Z › Every drug we've checked against herbs & supplements NDC & pricing lookup › Find a drug’s NDCs, packaging and costs Ask a pharmacist › Free, personal answer from our licensed team